HomeCompareOPORF vs EPRT

OPORF vs EPRT: Dividend Comparison 2026

OPORF yields 3.14% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPRT wins by $39.9K in total portfolio value
10 years
OPORF
OPORF
● Live price
3.14%
Share price
$0.09
Annual div
$0.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$384.28
Full OPORF calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — OPORF vs EPRT

📍 EPRT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOPORFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OPORF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OPORF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OPORF
Annual income on $10K today (after 15% tax)
$266.85/yr
After 10yr DRIP, annual income (after tax)
$326.64/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, EPRT beats the other by $10,868.58/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OPORF + EPRT for your $10,000?

OPORF: 50%EPRT: 50%
100% EPRT50/50100% OPORF
Portfolio after 10yr
$44.4K
Annual income
$6,777.57/yr
Blended yield
15.27%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

OPORF
No analyst data
Altman Z
3.9
Piotroski
6/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OPORF buys
0
EPRT buys
0
No recent congressional trades found for OPORF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOPORFEPRT
Forward yield3.14%3.97%
Annual dividend / share$0.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$24.5K$64.3K
Annual income after 10y$384.28$13,170.85
Total dividends collected$3.5K$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: OPORF vs EPRT ($10,000, DRIP)

YearOPORF PortfolioOPORF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$11,014$313.94$11,212$512.01$198.00EPRT
2$12,108$323.15$12,689$692.09$581.00EPRT
3$13,288$332.01$14,521$944.30$1.2KEPRT
4$14,558$340.52$16,841$1,302.88$2.3KEPRT
5$15,926$348.67$19,841$1,821.64$3.9KEPRT
6$17,397$356.48$23,818$2,587.47$6.4KEPRT
7$18,979$363.93$29,230$3,744.65$10.3KEPRT
8$20,679$371.05$36,816$5,540.38$16.1KEPRT
9$22,504$377.83$47,806$8,413.17$25.3KEPRT
10$24,464$384.28$64,324$13,170.85$39.9KEPRT

OPORF vs EPRT: Complete Analysis 2026

OPORFStock

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers. The Disease in Motion platform has various potential applications across a range of end users, including big technology, wearables, pharma, and biotech companies. Further, the company provides pre­clinical and early clinical research services; sales and marketing services; and biometry, data management, and statistics to its various European pharmaceutical clients, as well as drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), and PK and medical writing to a range of European clients. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.

Full OPORF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this OPORF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OPORF vs SCHDOPORF vs JEPIOPORF vs OOPORF vs KOOPORF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.